All In Biotech

Drug Trial Radar · NCT03773328

A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS)

Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 2022

Primary completion

Feb 2025

Study completion Feb 2027

Sponsor

Lead sponsor
Cellenkos, Inc.Industry
Sponsor type
Industry
First posted
Dec 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this research study is to determine whether it is safe and practical to give CK0801 (a cord-blood derived T-regulatory cell product) to patients with Guillain-Barré Syndrome (GBS). Researchers also want to determine the highest possible dose that is safe to be given and to learn if CK0801 may improve the symptoms of GBS. There will be three doses of CK0801 given during this study. A minimum of three patients will be treated in each dose level. The dose a patient receives is dependent on the timing of when they enter the study, as after each dose level is completed the following patients will receive the next highest dose level.

Conditions

  • Guillain-Barré Syndrome

Interventions

  • CK0801Biological

    CK0801 (Cord blood-derived T-regulatory cells)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0Time frame: 24 hours post-intervention
  2. Number of Participants with Regimen Related DeathTime frame: 30 days post-intervention
  3. Number of Participants with Severe Cytokine Release Syndrome (CRS)Time frame: 30 days post-intervention

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.